TCRT Stock Analysis: Buy, Sell, or Hold?
TCRT - Alaunos Therapeutics, Inc. Common Stock
$1.93
-0.06 (-3.02%)
▼
5d:
-26.34%
30d:
-26.62%
90d:
-44.38%
WAIT
LOW Confidence
Analysis Updated: Jun 9, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When TCRT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TCRT is down 26.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TCRT is down 26.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TCRT is currently trading at $1.93, which is considered oversold relative to its 30-day fair value range of $2.26 to $2.77.
Technical Outlook: Technically, TCRT is in a downtrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: TCRT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. However, the stock is trading significantly above the average Wall Street target of $1.75. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TCRT is in a downtrend. The price is currently testing key support at $1.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: TCRT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. However, the stock is trading significantly above the average Wall Street target of $1.75. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.26 -
$2.77
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BEARISH: Trading 12.1% above Wall St target ($1.75)
Trading Range Analysis
30-Day Trading Range
$2.26 -
$2.77
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.96
Resistance Level
$3.09
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.48
Wall Street Target
$1.75
(-12.1%)
Revenue Growth (YoY)
-25.0%
Share & Embed Analysis
Last updated: June 10, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 53 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 53 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
